JP2023055904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055904A5 JP2023055904A5 JP2023016174A JP2023016174A JP2023055904A5 JP 2023055904 A5 JP2023055904 A5 JP 2023055904A5 JP 2023016174 A JP2023016174 A JP 2023016174A JP 2023016174 A JP2023016174 A JP 2023016174A JP 2023055904 A5 JP2023055904 A5 JP 2023055904A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- composition
- antibody
- icos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1621782.0 | 2016-12-20 | ||
| GBGB1621782.0A GB201621782D0 (en) | 2016-12-20 | 2016-12-20 | Antibodies and immunocytokines PD-L1 specific antibodies and PD-L1 specific immunocytokines |
| GB1702339.1 | 2017-02-13 | ||
| GBGB1702339.1A GB201702339D0 (en) | 2017-02-13 | 2017-02-13 | Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines |
| GBGB1702338.3A GB201702338D0 (en) | 2017-02-13 | 2017-02-13 | Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines |
| GB1702338.3 | 2017-02-13 | ||
| GB1703071.9 | 2017-02-24 | ||
| GBGB1703071.9A GB201703071D0 (en) | 2017-02-24 | 2017-02-24 | Antibodies |
| US15/480,525 US10604576B2 (en) | 2016-06-20 | 2017-04-06 | Antibodies and immunocytokines |
| US15/480,525 | 2017-04-06 | ||
| GBGB1709818.7A GB201709818D0 (en) | 2017-06-20 | 2017-06-20 | Antibodies |
| PCT/GB2017/051795 WO2017220989A1 (en) | 2016-06-20 | 2017-06-20 | Anti-pd-l1 and il-2 cytokines |
| TW106120563 | 2017-06-20 | ||
| TW106120562A TWI784957B (zh) | 2016-06-20 | 2017-06-20 | 免疫細胞介素 |
| TW106120564 | 2017-06-20 | ||
| TW106120563A TW201803905A (zh) | 2016-06-20 | 2017-06-20 | 用於免疫腫瘤學之多重專一性抗體 |
| PCT/GB2017/051794 WO2017220988A1 (en) | 2016-06-20 | 2017-06-20 | Multispecific antibodies for immuno-oncology |
| TW106120564A TWI640536B (zh) | 2016-06-20 | 2017-06-20 | 抗體 |
| TW106120562 | 2017-06-20 | ||
| GBPCT/GB2017/051794 | 2017-06-20 | ||
| GBPCT/GB2017/051796 | 2017-06-20 | ||
| PCT/GB2017/051796 WO2017220990A1 (en) | 2016-06-20 | 2017-06-20 | Anti-pd-l1 antibodies |
| GBPCT/GB2017/051795 | 2017-06-20 | ||
| GB1709818.7 | 2017-06-20 | ||
| GBPCT/GB2017/052352 | 2017-08-09 | ||
| TW106126908A TWI760352B (zh) | 2016-08-09 | 2017-08-09 | 抗ｉｃｏｓ抗體 |
| PCT/GB2017/052352 WO2018029474A2 (en) | 2016-08-09 | 2017-08-09 | Anti-icos antibodies |
| TW106126908 | 2017-08-09 | ||
| PCT/GB2017/053826 WO2018115859A1 (en) | 2016-12-20 | 2017-12-19 | Multispecific antibody with combination therapy for immuno-oncology |
| JP2019533195A JP7290568B2 (ja) | 2016-12-20 | 2017-12-19 | 癌免疫療法のための併用療法での多重特異性抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533195A Division JP7290568B2 (ja) | 2016-12-20 | 2017-12-19 | 癌免疫療法のための併用療法での多重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023055904A JP2023055904A (ja) | 2023-04-18 |
| JP2023055904A5 true JP2023055904A5 (enExample) | 2023-12-04 |
| JP7750887B2 JP7750887B2 (ja) | 2025-10-07 |
Family
ID=61192960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533195A Active JP7290568B2 (ja) | 2016-12-20 | 2017-12-19 | 癌免疫療法のための併用療法での多重特異性抗体 |
| JP2023016174A Active JP7750887B2 (ja) | 2016-12-20 | 2023-02-06 | 癌免疫療法のための併用療法での多重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533195A Active JP7290568B2 (ja) | 2016-12-20 | 2017-12-19 | 癌免疫療法のための併用療法での多重特異性抗体 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20200190191A1 (enExample) |
| EP (1) | EP3559041A1 (enExample) |
| JP (2) | JP7290568B2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116640214A (zh) * | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) * | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| CA3171597A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CN115698075A (zh) * | 2020-04-14 | 2023-02-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗 |
| WO2022243378A1 (en) * | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| WO2023057534A1 (en) * | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
| EP4525991A1 (en) * | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2775761C (en) * | 2009-09-30 | 2018-08-28 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| RS60614B1 (sr) * | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| CN116640214A (zh) * | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| EP3728314A1 (en) * | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
-
2017
- 2017-12-19 US US16/471,161 patent/US20200190191A1/en not_active Abandoned
- 2017-12-19 EP EP17840565.0A patent/EP3559041A1/en active Pending
- 2017-12-19 JP JP2019533195A patent/JP7290568B2/ja active Active
-
2023
- 2023-02-06 JP JP2023016174A patent/JP7750887B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055904A5 (enExample) | ||
| JP2020502198A5 (enExample) | ||
| JP2022191301A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2020528768A5 (enExample) | ||
| JP2020536109A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2012523417A5 (enExample) | ||
| JP2020518598A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| WO2019160751A3 (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| NZ723369A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JPWO2020132066A5 (enExample) | ||
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| JP2020533382A5 (enExample) | ||
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| JP2013538813A5 (enExample) |